Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: guo l. Dermatol Ther (Heidelb). 2023 Feb;13(2):629-640. doi: 10.1007/s13555-022-00879-8. Epub 2022 Dec 31. Dermatol Ther (Heidelb). 2023. PMID: 36585606 Free PMC article.
Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA.
Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, Shan Y, Rebello S, Guo L, Khaychuk V. Harrold LR, et al. Among authors: guo l. Rheumatol Ther. 2022 Apr;9(2):465-480. doi: 10.1007/s40744-021-00401-0. Epub 2021 Dec 23. Rheumatol Ther. 2022. PMID: 34940957 Free PMC article.
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: guo l. Dermatol Ther (Heidelb). 2023 Feb;13(2):487-504. doi: 10.1007/s13555-022-00865-0. Epub 2022 Dec 9. Dermatol Ther (Heidelb). 2023. PMID: 36484917 Free PMC article.
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier DH. Pappas DA, et al. Among authors: guo l. Arthritis Res Ther. 2023 Sep 9;25(1):166. doi: 10.1186/s13075-023-03120-9. Arthritis Res Ther. 2023. PMID: 37689684 Free PMC article.
21,689 results
You have reached the last available page of results. Please see the User Guide for more information.